Business● Low2h ago · Nov 5, 2026, 3:55 AM
PacBio narrows 2026 revenue guidance to $155M-$160M while targeting cash flow breakeven in 2028
GlobeAlert Desk · curated from Seeking Alpha Tech · global
PacBio has updated its financial projections, narrowing its 2026 revenue guidance to between $155 million and $160 million. The company is also aiming to achieve cash flow breakeven by 2028.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business23m agoDatsoho: How FG’s policies boosted export growth by 25% in two yearsPremium TimesBusiness25m agoNewAmsterdam Pharma GAAP EPS of -$0.14 beats by $0.30, revenue of $19.16M beats by $4.11MSeeking Alpha TechBusiness25m agoShares advance after Wall Street rally following US midterm electionsEuroNews [en]Business28m agoStella-Jones outlines up to $100M in 3-year cost savings while targeting full Candiac run rate by end of Q1 2027Seeking Alpha Tech